Name: UMIN ID:
Unique ID issued by UMIN | UMIN000029982 |
---|---|
Receipt number | R000034244 |
Scientific Title | A Retrospective Study of Safety and Efficacy for Re-treatment of Brentuximab-Vedotin (BV) in Patients With Relapsed/Refractory (R/R) classical Hodgkin Lymphoma (cHL)/ systemic Anaplastic Large-cell Lymphoma (sALCL) |
Date of disclosure of the study information | 2017/11/15 |
Last modified on | 2019/09/02 19:15:29 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2017/11/15 13:51:46 | ||
2 | Update | 2017/11/15 13:56:00 | Organization1 Address1 Tel1 |
|
3 | Update | 2018/01/10 12:42:54 | Recruitment status |
|
4 | Update | 2018/08/03 12:12:07 | Recruitment status Last follow-up date Date of closure to data entry |
|
5 | Update | 2019/09/02 18:57:48 | Recruitment status Date of IRB Date trial data considered complete Date analysis concluded |
|
6 | Update | 2019/09/02 19:12:45 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
7 | Update | 2019/09/02 19:15:29 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Zip code Address Organization Organization Address Address Tel |